Search

Tirapazamine

It is important to take into consideration that normally, the cells in these hypoxic regions are resistant to radiotherapy and most anticancer drugs. … For all these reasons, the combination of tirapazamine with other anticancer treatments is highly recommended.

Silver sulfadiazine

Silver sulfadiazine is a sulfa derivative topical antibacterial used primarily on second- and third-degree burns.

Phenprocoumon

Coumarin derivative that acts as a long-acting oral anticoagulant.

Sulfaphenazole

Sulfaphenazole is a sulfonamide antibacterial.

Bifemelane

Cytisine

Cytisine is an alkaloid naturally derived from the Fabaceae family of plants including the genera Laburnum and Cytisus. … Recent studies have shown it to be a more effective and significantly more affordable smoking cessation treatment than nicotine replacement therapy.

1D09C3

The antibody was isolated in collaboration with MorphoSys from its HuCAL(R) library of human antibodies. 1D09C3 binds to certain cell surface receptors, selectively killing activated, proliferating MHC … class II-positive tumor cells, which include those in B-cell and T-cell lymphomas. 1D09C3 has been shown to induce programmed cell death and does not require a functioning immune system for its cell-killing

Banoxantrone

It has been shown to work synergistically with fractionated radiation to significantly delay growth of tumours compared to administration of either banoxantrone or radiation alone. … Banoxantrone is a highly selective bioreductive drug that is activated in, and is preferentially toxic to, hypoxic cells in tumours.

Orgotein

Hydrogen peroxide can be degraded by catalase. The antioxidant mechanism of SOD is common to most organisms exposed to oxygen. A notable exception is Lactobacillus plantarum. … Superoxide dismutase (SOD) is an enzyme that alternately catalyzes the dismutation of the superoxide radical into either the less damaging hydrogen peroxide or molecular oxygen.

Volixibat

If approved for use, it will be the first available agent for the treatment of NASH. … According to Shire, the pharmaceutical manufacturer of Volixibat, it has been granted fast track status by the Food and Drug Administration due to promising initial results and a need for therapeutic treatments